

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/943,380	08/30/2001	S. Grant Mulholland	10303-2 US	7757	
7:	590 03/24/2004		EXAMINER		
	MONACO, ESQ.		LAM, ANN Y		
DRINKER BIDDLE & REATH, LLP ONE LOGAN SQUARE			ART UNIT	PAPER NUMBER	
18TH AND CH	IERRY STREETS	••	1641	N.	
PHILADELPH	IIA, PA 19103-6996		DATE MAILED: 03/24/2004	004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	09/943,380	MULHOLLAND ET AL.					
Office Action Summary	Examiner	Art Unit					
,	Ann Y. Lam	1641					
The MAILING DATE of this communication							
Period for Reply							
A SHORTENED STATUTORY PERIOD FOR F THE MAILING DATE OF THIS COMMUNICAT - Extensions of time may be available under the provisions of 37 C after SIX (6) MONTHS from the mailing date of this communicati - If the period for reply specified above is less than thirty (30) days - If NO period for reply is specified above, the maximum statutory - Failure to reply within the set or extended period for reply will, by Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	ION. CFR 1.136(a). In no event, however, ion. i, a reply within the statutory minimum period will apply and will expire SIX (6 statute, cause the application to become	nay a reply be timely filed of thirty (30) days will be considered timely. b) MONTHS from the mailing date of this communication. ome ABANDONED (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on	29 December 2003.						
,	This action is non-final.						
•	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
closed in accordance with the practice ur	ider Ex parte Quayle, 193:	5 C.D. 11, 453 O.G. 213.					
Disposition of Claims							
4) Claim(s) <u>1-6,8-64 and 73-75</u> is/are pendi	ng in the application.						
4a) Of the above claim(s) is/are wi	thdrawn from consideration	ղ.					
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>1-6, 8-64 and 73-75</u> is/are rejected.							
,	7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction	and/or election requiremer	t.					
Application Papers							
9)☐ The specification is objected to by the Exa							
10) The drawing(s) filed on is/are: a)	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection							
•		awing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by t	he Examiner. Note the atta	ached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for for a) All b) Some * c) None of: 1. Certified copies of the priority docu	ıments have been receive	d.					
2. Certified copies of the priority docu							
 Copies of the certified copies of the application from the International E 		been received in this National Stage					
* See the attached detailed Office action for							
Attachment(s)	-	(DTC 140)					
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-9) 	_	rview Summary (PTO-413) er No(s)/Mail Date					
Information Disclosure Statement(s) (PTO-1449 or PTO/Paper No(s)/Mail Date		ce of Informal Patent Application (PTO-152)					

Art Unit: 1641

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-4, 8-11, 13-15, 18-23, 32-36, 39-42, 44-50, 58, 61, and 64 are rejected under 35 U.S.C. 102(e) as being anticipated by D'Augustine et al., 6,416,779.

As to claims 1, 33, 61 and 64, D'Augustine et al. disclose a base member (47) that is non-meltable; a reinforcement (44) that is non-meltable and has a length having a first end and a second end, said first end attached to said base member and projecting from said base member; and a meltable portion (i.e., medication in 43) formed around a portion of said length of said reinforcement, said meltable portion having a diameter which tapers from said second end toward said first end, see Figure 6.

As to claims 2, 34, the base member (47) is shaped for handling.

As to claims 3, 4, 35, 36, the base member (47) is ellipsoid.

As to claim 39, the base member (47) is sized to fit within the labia minora.

Art Unit: 1641

As to claims 8, 13, 22, 40, 44 and 49, the suppository is comprised of polymers, see column 15, lines 18-22.

As to claims 9, 10, 41, the reinforcement first end is consideredembedded within the base member, and projects perpendicular from said base member, see Figure 6.

As to claims 11, 42, the reinforcement (44) comprises a rod.

As to claim 14, the reinforcement is sized such that upon insertion into the urethra, the second end of the reinforcement is entirely within the meltable portion.

As to claim 15, the second end of the reinforcement (44) extends outside the meltable portion, see Figure 6.

As to claims 18-21, 45-48, the reinforcement (44) comprises a restraint.

As to claims 23, 50, the meltable portion comprises the therapeutic agents as claimed, see column 20, lines 39-43.

As to claim 32, 58, the meltable portion is capable of melting within about 2 minutes to about 60 minutes.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 24, 25, 31, 51, 52, 57, 62, 63 and 73-75 are rejected under 35 U.S.C. 103(a) as being unpatentable over D'Augustine et al., 6,416,779.

Art Unit: 1641

D'Augustine et al. disclose the invention substantially as claimed (see above).

However, with respect to claims 16, 17, 24, 25, 30, 31, 51, 52, 57, 59, 60 and 73-75, D'Augustine et al. do not disclose the dimensions as claimed. However, it would have been obvious to form the meltable portion having the dimensions as claimed, as would be necessary to fit inside the vagina of patients of various sizes, as taught by D'Augustine et al.

As to claims 62 and 63, it would have been obvious to wait for about 1 minute to about 10 hours to deliver the therapeutic agent, as may be necessary to deliver the agent.

Allowable Subject Matter

Claims 5, 6, 12, 26-29, 37-38, 43, 53-56 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

The following is a statement of reasons for the indication of allowable subject matter: the combination of elements including a grooved base member, or a roughened base member, or a reinforcement being comprised of a lattice or mesh, was not found in the prior art search.

Response to Arguments

Applicant's arguments filed December 29, 2003 have been fully considered but they are not persuasive. Applicant argues that none of the materials

Art Unit: 1641

disclosed by D'Augustine for the foam portion (43) is meltable, and that assuming that the medication was meltable, however, the foam portion (43) defining the tapered member for the tampon device will not melt (see page 2 of Applicant's response).

In response, Examiner asserts that the medication is considered the meltable portion formed around a portion of the length of the reinforcement (44) and having a diameter which tapers, as claimed by Applicant. Thus, it is irrelevant as the rejection, that the foam portion (43) will not melt.

Applicant also argues on page 2 that the reinforcement (44) is not embedded within the base member (47), but rather is adjacent to it. Examiner asserts that the reinforcement is embedded within the base member to the extent that the member (47) is attached to member (44) (see column 15, lines 20-22).

Applicant argues that Augustine does not disclose that an end of the reinforcement opposite the base member extends outside the meltable portion. Examiner asserts that the end opposite the base member includes a portion that remains outside the meltable portion (see Figure 6).

Applicant argues on page 3 that Augustine does not disclose that the reinforcement comprises one or more restraints along the portion of the length of the reinforcement, but rather the tube (44) is uniform along the length that is surrounded by the tapering foam portion (43).

In response, Examiner points out the tube (44) is not entirely uniform, but rather has an end that tapers to a wider width until it becomes cylindrical (see Figure 6.) The

Art Unit: 1641

cylindrical portion is considered a restraint, i.e., a protrusion having the form of a rod, as claimed by Applicant.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ann Y. Lam whose telephone number is (703) 306-5560. The examiner can normally be reached on M-Sat 11-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on (703)305-3399. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Art Unit: 1641

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703)308-0196.

A.L.

LONG V. LE SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

03/12/04

Page 7